Morris Z. Rosenberg
Keine laufenden Positionen mehr
Profil
Morris Z.
Rosenberg worked as a Group Leader at Biogen MA, Inc. from 1990 to 1998.
He then worked as the Head-Bioprocess Development at Eli Lilly & Co. from 1998 to 2001.
In 2004, he joined Seagen Inc. and worked there as the Executive Vice President-Process Sciences from 2009 to 2012.
From 2018 to 2020, he worked as the Chief Technology Officer at Immunomedics, Inc. Rosenberg received his undergraduate, graduate, and doctorate degrees from Washington University in St. Louis.
Ehemalige bekannte Positionen von Morris Z. Rosenberg
| Unternehmen | Position | Ende |
|---|---|---|
| IMMUNOMEDICS, INC. | Chief Tech/Sci/R&D Officer | 15.05.2020 |
| SEAGEN INC. | Corporate Officer/Principal | 01.06.2012 |
| ELI LILLY AND COMPANY | Corporate Officer/Principal | 01.07.2001 |
Biogen MA, Inc.
 Biogen MA, Inc. BiotechnologyHealth Technology Biogen MA, Inc. is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. The company’s research and development activities used to focus on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases, developmental biology and gene therapy. The company was founded by Daniel D. Adams in 1976 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01.07.1998 |
Ausbildung von Morris Z. Rosenberg
| Washington University in St. Louis | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| ELI LILLY AND COMPANY | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Biogen MA, Inc.
Biogen MA, Inc. BiotechnologyHealth Technology Biogen MA, Inc. is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. The company’s research and development activities used to focus on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases, developmental biology and gene therapy. The company was founded by Daniel D. Adams in 1976 and is headquartered in Cambridge, MA. | Health Technology |
Immunomedics, Inc.
 Immunomedics, Inc. BiotechnologyHealth Technology Immunomedics, Inc. researching, developing, manufacturing, and marketing biopharmaceutical products. It focuses on monoclonal antibody-based products for the targeted treatment of cancer. The company was founded by David M. Goldenberg in July 1982 and is headquartered in Morris Plains, NJ. | Health Technology |
Seagen Inc.
 Seagen Inc. Pharmaceuticals: MajorHealth Technology Seagen Inc. is a biotechnology company, which engages in the development and commercialization of targeted therapies for the treatment of cancer. It also focuses on the advancement of therapies for solid tumors and blood-related cancers. Its products include Adcetris, Padcev, Tivdak, and Tukysa. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA. | Health Technology |
